Clinical trials: Dapagliflozin
Type2diabetes
DM Treatment to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone in Patients with Type 2 Diabetes
Key finding of DM Treatment with combination, A MuLticenter, Randomized, Parallel, Gathering Information of phase 4 Trial to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone add-on to Metformin and DPP-4…
- Trial name
- KLIMT (NCT06875193)
- Testing
- DW6012(Dasidiem tab. 10/100mg)
- Where
- South Korea
- Volunteers
- 196 people
- Sponsor
- Dong Wha Pharmaceutical Co. Ltd.
Type 2 Diabetes Mellitus
Effects of Dapagliflozin on Insulin Resistance and Insulin Secretion in Subjects With Type 2 Diabetes
The purpose of this study is to evaluate the effects of dapagliflozin on insulin sensitivity
- Trial name
- NCT00831779
- Testing
- Dapagliflozin
- Where
- 3 sites in United States
- Volunteers
- 116 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
A Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy
The purpose of this study is to identify the risk of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes in clinical practice and to evaluate the clinical usefulness of Dapagliflozin/Pioglitazone…
- Trial name
- NCT06649162
- Where
- 2 sites in South Korea
- Volunteers
- 10,000 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Diabetes Mellitus
A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fasting)
This was an open-label, randomized, fasting, single-dose, 2-sequence, 2-period crossover study to evaluate the pharmacokinetics and safety between single oral administration of "BR3006" and co-administration of "BR3006A"…
- Trial name
- NCT07083388
- Testing
- Dapagliflozin 10 mg/Pioglitazone 30 mg/Metformin HCl 1000 mg, Dapagliflozin 10 mg, Pioglitazone 30 mg
- Where
- South Korea
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Type2 Diabetes Mellitus
Saxagliptin in Combination With Dapagliflozin - Effects on Islet Cell Function
The purpose of this study is to evaluate alpha- and beta-cell function during combination treatment with saxagliptin in addition to dapagliflozin and metformin compared to placebo in addition to dapagliflozin and metformin in…
- Trial name
- NCT02304081
- Testing
- Saxagliptin
- Where
- Germany
- Volunteers
- 64 people
- Sponsor
- Prof. Dr. Thomas Forst
Type 2 Diabetes
forREAL: FORXIGA PRESCRIPTION EVENT MONITORING PROGRAM (PEMP)
The study purpose is to assess adverse events in patients with Type 2 diabetes who have newly been prescribed Forxiga for the management of glycemic control
- Trial name
- forREAL (NCT01944618)
- Testing
- Forxiga
- Where
- Australia
- Volunteers
- 5,000 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2, Skeletal Muscle Insulin Sensitivity
Effects of 5 Weeks Treatment With Dapagliflozin in Type 2 Diabetes Patients on How the Hormone Insulin Acts on Sugar Uptake in Muscles.
The purpose of this study is to investigate the effects of 5 weeks treatment with dapagliflozin in type 2 diabetes patients on how the hormone insulin acts on sugar uptake in muscles.
- Trial name
- DAPAMAAST (NCT03338855)
- Testing
- Dapagliflozin
- Where
- Netherlands
- Volunteers
- 26 people
- Sponsor
- AstraZeneca
Renal Insufficiency, Chronic
A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)
The purpose of this study is to evaluate the efficacy, safety and tolerability of balcinrenone in fixed combination with dapagliflozin, compared with dapagliflozin, in patients with CKD Stage 3b and 4 (eGFR ≥ 15 to < 45…
- Trial name
- NCT07624305
- Testing
- Balcinrenone/dapagliflozin, Dapagliflozin
- Where
- 478 sites in United States, Argentina and 25 more
- Volunteers
- 2,800 people
- Sponsor
- AstraZeneca
Diabetes
Phase III Insulin Add-On Asia Regional Program - ST
The purpose is to determine if after 24 weeks of oral daily administration, there will be a greater mean reduction from baseline in glycosylated hemoglobin (HbA1c) achieved with Dapagliflozin 10 mg plus insulin compared to…
- Trial name
- NCT02096705
- Testing
- Dapagliflozin
- Where
- 29 sites in China, Singapore and 1 more
- Volunteers
- 477 people
- Sponsor
- AstraZeneca
PreDiabetes, Myocardial Infarction
Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction
It is hypothesize that, because dapagliflozin will reverse the metabolic defects responsible for the development of prediabetes (i.e.
- Conditions
- PreDiabetes, Myocardial Infarction, T2DM (Type 2 Diabetes Mellitus), CVD
- Trial name
- NCT03658031
- Testing
- Dapagliflozin 10mg
- Where
- Qatar
- Volunteers
- 576 people
- Sponsor
- Hamad Medical Corporation
Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure
The purpose of this study is to evaluate the effect of dapagliflozin on the incidence of worsening heart failure or cardiovascular death in patients with chronic heart failure with reduced ejection fraction
- Trial name
- DAPA-HF (NCT03036124)
- Testing
- Dapagliflozin
- Where
- 419 sites in United States, Argentina and 18 more
- Volunteers
- 4,744 people
- Sponsor
- AstraZeneca
Acute Kidney Injury
Acute Kidney Injury in Patients on Dapagliflozin and Other Antidiabetic Medications
To compare, by insulin use at the index date, the incidence of hospitalization for acute kidney injury (AKI) among patients with type 2 diabetes mellitus who are new users of dapagliflozin with those who are new users of…
- Trial name
- NCT02695082
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 539,310 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight/Obese Participants With Type 2 Diabetes
A Phase 2 study Comparing the effects on glucose control of MEDI0382 in combination with Dapagliflozin and Metformin compared to placebo in combination with Dapagliflozin and Metformin in overweight/obese participants with Type 2…
- Trial name
- NCT03444584
- Testing
- MEDI0382, Dapaglifozin, Metformin
- Where
- 8 sites in Germany, Hungary and 1 more
- Volunteers
- 49 people
- Sponsor
- MedImmune LLC
Chronic Kidney Disease
Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial)
The purpose of the study is to assess efficacy, safety and tolerability of treatment with zibotentan and dapagliflozin in combination and dapagliflozin 10 mg as monotherapy in participants with chronic kidney disease (CKD) with…
- Trial name
- ZENITH-CKD (NCT04724837)
- Testing
- Zibotentan, Dapagliflozin
- Where
- 164 sites in United States, Argentina and 17 more
- Volunteers
- 542 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)
The purpose of the study is to assess the effect of the addition of sitagliptin to metformin with or without a sulfonylurea compared with the addition of dapagliflozin to metformin with or without a sulfonylurea on hemoglobin A1c…
- Trial name
- NCT02532855
- Testing
- Sitagliptin, Dapagliflozin, Metformin
- Volunteers
- 614 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy Adult Volunteers
Clinical Trial to Compare Pharmacokinetics After Administration of ATB-101 or Co-administration of ATB-1011 and ATB-1012
To compare and evaluate safety and pharmacokinetic Characteristics after administration of ATB-101 or co-administration of ATB-1011 and ATB-1012 in fasted Healthy Adult Volunteers
- Trial name
- NCT05017987
- Testing
- ATB-101, ATB-1011, ATB-1012
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Autotelicbio
Chronic Kidney Disease
Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy Participants
The study will have 2 independent parts: Part 1 of the study is intended to collect samples for Metabolites in Safety Testing (MIST) analysis after administration of multiple doses of zibotentan.
- Trial name
- NCT04991571
- Testing
- Zibotentan (Treatment A), Dapagliflozin (Treatment A), Zibotentan/Dapagliflozin - Formulation 1 (Treatment B)
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus, Type 2 Diabetes With Chronic Kidney Disease
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron, compared with placebo in adults with type 2 diabetes mellitus (T2DM) and impaired renal function, who are or will be on a background…
- Trial name
- Eluminate-4 (NCT07662135)
- Testing
- Elecoglipron
- Where
- 186 sites in United States, Bulgaria and 14 more
- Volunteers
- 900 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin
This is a 24-week, multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel group, phase 3 study designed to evaluate if the safety and efficacy of dapagliflozin 5 mg or 10 mg added to saxagliptin 5 mg…
- Trial name
- NCT03608358
- Testing
- Dapagliflozin 10 mg, Dapagliflozin 5 mg, Saxagliptin 5 mg
- Where
- 4 sites in Thailand, Vietnam
- Volunteers
- 41 people
- Sponsor
- AstraZeneca
Heart Failure, Volume Overload
Safety & Feasibility of DSR TherApy in Heart FAiluRe pAtients With Persistent Congestion
Feasibility and safety study of the alfapump DSR system in the treatment of volume overloaded heart failure subjects receiving high doses of loop diuretics.
- Trial name
- SAHARA (NCT04882358)
- Testing
- ALFAPUMP DSR (DIRECT SODIUM REMOVAL) SYSTEM, SGLT2 inhibitor
- Where
- 2 sites in Georgia
- Volunteers
- 24 people
- Sponsor
- Sequana Medical N.V.